SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear? -- Ignore unavailable to you. Want to Upgrade?

To: Bluegreen who wrote (16059)9/12/2002 6:32:04 PM
From: tom pope  Read Replies (1) | Respond to of 17367
 
Biogen sees FDA finishing Amevive review in 6 months
Thursday September 12, 6:19 pm ET

CAMBRIDGE, Mass., Sept 12 (Reuters) - Biogen Inc. (NasdaqNM:BGEN - News) on Thursday said U.S. regulators would complete a review of its application for psoriasis drug Amevive within six months.
The Cambridge, Massachusetts-based company said it expected the application was on track for approval in early 2003 by the U.S. Food and Drug Administration. Psoriasis is a skin inflammation disorder.



To: Bluegreen who wrote (16059)9/20/2002 11:22:07 PM
From: Cacaito  Read Replies (2) | Respond to of 17367
 
11,000 subjects trial, Lilly is going to expend some $100M in Xigris trial, even if they do not get improvement in subjects it will pay for Lly if they just prove no harm it is open highway for the drug in the subjects were proven effective.

Bpi is on a leash and on meager diet, thanks to bax. Sad.


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News